DNA Vaccines-How Far From Clinical Use?

Hobernik D, Bros M. · 2018

Read DNA Vaccines-How Far From Clinical Use? by Hobernik D, Bros M. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6274812.txt.

Introduction

Hobernik and Bros ask how close DNA vaccines are to routine clinical use. Their review appeared in the International Journal of Molecular Sciences. DNA vaccines deliver gene instructions instead of ready made protein. They are cheap to make, stable, and safe to handle. Over five hundred trials are registered in the United States alone. Targets centre on viral infections and cancer.

Human immune responses have so far been weaker than hoped. The review traces where the signal gets lost. Carriers can shield DNA from breakdown on its way into cells. Added sequences can guide DNA into the cell nucleus. Designs can use promoters that work only in presenting cells. Extra gene cargo can block tolerance and lift response. The authors argue that stacking all these fixes may be needed. Combination with other drugs may also be part of the answer.

Catalog record

CREATORHobernik D, Bros M.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE107 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6274812

Browse the full library · About the Tower of Babel